Arpita Desai, MD
Assistant Professor
Medicine
School of Medicine
Dr. Arpita Desai is an oncologist who specializes in the treatment of patients with genitourinary cancers, in particular kidney and prostate cancers. She is the Medical Director of the GU Medical Oncology program at UCSF
Show full bio (100 words) Hide full bio
Desai is interested in developing novel imaging and therapeutic strategies in renal cell cancer with the goal of improving outcomes by personalizing therapy. The scope of her most recent work has been related to incorporating functional and molecular imaging to personalize treatment in GU malignancies.
Desai completed her residency in internal medicine at the State University of New York where she also served as chief resident of internal medicine. She completed a fellowship in medical oncology at the University of Chicago. She is a member of the American Society of Clinical Oncology (ASCO) and American Association for Cancer Research (AACR).
Awards
Show all (6) Hide
- Prostate Cancer Program Pilot Research Award, Prostate Cancer Program UCSF, 2022
- HDFCC UCSF Junior Clinical Investigator Award, UCSF, 2020
- Conquer Cancer Foundation of ASCO/Frances A. Shepherd, MD, Endowed Merit Award, ASCO, 2018
- Young Investigator Award, IASLC, 2018
- Thomas F. Frawley Research Fellowship Award, SUNY at Buffalo, 2015
- Dexter S. Levy Memorial Award, SUNY at Buffalo, 2014
Education & Training
Show all (2) Hide
- Fellowship Medical Oncology University of Chicago 2018
- Residency Internal Medicine State University of New York at Buffalo 2015
Publications (16)
Top publication keywords:
Prostatic Neoplasms, Castration-ResistantAnilidesMolecular Diagnostic TechniquesProstate-Specific AntigenVon Hippel-Lindau Tumor Suppressor ProteinAntigens, SurfaceCarcinoma, Renal CellUrologic NeoplasmsKidney NeoplasmsGlutamate Carboxypeptidase IIPyridinesProtein Kinase InhibitorsKallikreinsReceptors, Vascular Endothelial Growth FactorUrothelium
-
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
Journal of the National Comprehensive Cancer Network : JNCCN 2024 Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King … -
Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma.
Cancer drug resistance (Alhambra, Calif.) 2023 Sweeney PL, Suri Y, Basu A, Koshkin VS, Desai A -
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
The Lancet. Oncology 2023 Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong… -
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
Clinical genitourinary cancer 2023 Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal … -
Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
Frontiers in oncology 2023 Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou…
Show all (11 more) Hide
-
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
Urologic oncology 2022 Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ -
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer.
The oncologist 2022 Freeman MN, Jang A, Zhu J, Sanati F, Nandagopal L, Ravindranathan D, Desai A, Phone A, Nussenzveig R, Jaeger E, Caputo SA, Koshkin VS, Swami U, Basu A, Bilen MA, Agarwal N, Sartor O, Burgess EF, … -
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
Frontiers in oncology 2022 Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J,… -
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET… -
Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer.
JCO oncology practice 2021 Kwon DH, Karthikeyan S, Chang A, Borno HT, Koshkin VS, Desai A, Bose R, Friedlander T, Rodvelt T, Li P, Small EJ, Aggarwal RR, Belkora J -
TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
Journal for immunotherapy of cancer 2021 de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, … -
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
Cancer 2021 Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS -
Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer.
Cancer medicine 2020 Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S, Hope TA -
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort.
Frontiers in oncology 2020 Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA -
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau … -
Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.
Future oncology (London, England) 2019 Desai A, Small EJ